CPHI Milan 2024: Improving Efficiency and Reducing Costs for Oral Solid Dosage Forms

Pharmaceutical Technology^® Europe caught up with Michelle Logan, vice president of the drug product division at Thermo Fisher Scientific, at CPHI Milan to discuss the oral solid dosage (OSD) forms market, its key trends and challenges, the affordability of these drugs within the market, and how OSD developers and manufacturers can drive those costs down and improve efficiencies in their processes at the same time.

“We are really focused around expanding capability and the early development side of things, so we can start earlier on with our customers and transition them through successfully all the way to commercialization,” Logan said in the interview. “So, you'll see that as some of our main offerings and focus, as we continue to expand and support capacity in this space.”

Logan said the digital space is an area Thermo Fisher has identified as wanting to increasingly use to its advantage.

“I think when you think about our commercial capacity that we have, the more we can leverage digital to drive initiatives improvements like line functionality, the better it is for our customers,” she said. “At the end of the day, that's really around the automation side of things ... our oral solid dose customers are leveraging routinely with us to help save from a cost perspective.”

Click the above video to watch the full interview.

Visit Thermo Fisher Scientific at Booth 7B18. CPHI Milan is being held from Oct. 8–10, 2024 in Milan, Italy.